Search

Mupadolimab

CPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy. … NCT03454451 focused on advanced cancers (e.g., non-small cell lung cancer, renal cell cancer, colorectal cancer).

Marimastat

Used in the treatment of cancer, Marmiastat is an angiogenesis and metastasis inhibitor. As an angiogenesis inhibitor it limits the growth and production of blood vessels. … As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.

Alunacedase alfa

Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.

C11-12 isoparaffin

C11-12 isoparaffin is a mixture of branched chain hydrocarbons with 11C or 12C's in the alkyl chain. It is found in cosmetic and personal care products as solvents or skin conditioning agent.

Abarelix

It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.

NE-180

NE-180 was under investigation in a clinical trial conducted in the European Union.

Sonepcizumab

Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis. … A humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities.

AN0128

Of particular importance is P. acnes and its causal role in acne vulgaris. The rise in antibiotic resistance of P. acnes to standard antibiotics necessitates the development of new treatment agents. … AN0128 is a novel compound that contains a boron atom within a borinic acid complex.

AVE9633

AVE9633 is an anti-CD33 monoclonal antibody-DM4 conjugate.

Polyinosinic-polycytidylic acid